However, there is a question we rarely ask when introducing a new technology, administrative requirement or checkpoint process into health: “Did we actually eliminate work, or did we simply kick the can down the road and move it to someone else?”

Too often, what looks like efficiency on one side of the health ecosystem table is experienced as friction on the other. The insurer automates a process while a physician practice hires someone to navigate it. The hospital creates another digital portal, while the patient becomes responsible for connecting information that the health system has failed to connect with another. New technology promises to give clinicians time back, only to add another inbox, alert, or screen demanding attention.

In Healing the Sick Care System: Why People Matter, I describe fragmentation as one of the forces that separates people from the care they need and health professionals from the people they are trying to help. Friction is what that fragmentation feels like in our day-to-day life. It is the extra call, the repeated form, the missing information, the wasted hour and the handoff nobody owns. Worse, it is the yelling and arguing between the patient’s physician and the payer’s prior authorization approval team.

There is a cost to all of this. Call it the friction tax.

The Work Did Not Disappear

Prior authorization offers one of the clearest examples. It is intended to control unnecessary spending and encourage appropriate use of diagnostics and treatments. Those are legitimate, responsible goals. The problem amplifies when the administrative mechanism created to save money begins consuming enormous resources elsewhere.

The American Medical Association reported in 2026 that physicians and their staff spend an average of 13 hours each week completing prior authorization requirements. Physicians average about 40 authorization requests each week and 40 percent report having staff who work exclusively on prior authorization.

That work is not free. Its cost simply moved.

An insurer’s utilization decision results in forms, electronic submissions, phone calls, appeals, and follow-up work within a physician practice. Even when the authorization is eventually approved, someone has paid the friction tax. The patient may pay another portion through delayed treatment or by exhausting the effort required to fight for something a clinician has already determined to be necessary. In rare but tragic cases, the friction does not merely delay care. It helps determine whether care arrives in time.

We celebrate efficiency where it was created, without always counting the burden it created elsewhere.

When Waiting Becomes a Bill

Consider something far more ordinary: waiting for the doctor.

Physicians run late. Medicine is unpredictable and sometimes the person in the examination room needs more time than anyone anticipated. That is not friction. The friction is knowing the doctor is running 30, 60 or 90 minutes behind and failing to tell the next patient.

The technology needed to send a text saying, “Dr. Smith is running about 45 minutes late. Please adjust your arrival time,” is hardly futuristic. Airlines alert us when our flights are delayed. Restaurant buzzers tell us when a table is ready. A delivery app can show us a sandwich moving across town. Even items ordered from other countries have shopper apps to keep us posted on their global journeys.

Yet people still leave work, arrange childcare, drive to a physician’s office and sit for an hour because nobody communicated information the practice already knew. This is where a simple principle becomes very practical: communication is care. A timely message respects someone’s time, reduces anxiety and helps strengthen ties before the health encounter even begins.

People’s time has economic value. A national study published in The American Journal of Managed Care found that an ambulatory medical visit lasted an average of 121 minutes, including 37 minutes of travel and 84 minutes at the clinic. Researchers estimated the opportunity cost at $43 per visit in 2010, totaling approximately $52 billion annually across the United States. For every dollar spent reimbursing a physician visit, patients absorbed another 15 cents in the value of their time.

Those figures are more than a decade old; however, the principle is not. Every unnecessary 30 or 60 minutes has value, particularly for the hourly worker losing wages, the parent paying for childcare, the caregiver juggling another person’s needs or anyone forced to surrender a piece of the workday because a practice did not communicate.

According to the American Family Physician, 10 million patients visited a primary care physician this week. Multiply that experience across millions of appointments and waiting stops being a minor annoyance. It becomes an enormous invisible expense.

People Eventually Route Around Friction

There is another consequence to inconvenience that cannot be measured only in dollars. People change their behavior using their buying power.

Urgent care centers and retail clinics offer something traditional medicine too often lacks: walk-in availability, extended hours and shorter waits. Research examining retail clinic use has repeatedly identified convenience as an important reason patients choose these settings.

That matters because people eventually route around friction.

The growth of convenient care cannot be attributed to waiting rooms alone. Primary care shortages, appointment availability, location, cost and changing consumer expectations all played roles. Yet convenience became a competitive advantage because traditional primary care frequently asked patients to organize their lives around the system rather than designing the system around people’s lives.

The loss can be subtle. A walk-in clinic can treat a sore throat or an infection just as efficiently. What it cannot always replace is the long-standing relationship with a primary care professional who has known the patient over the years, notices changes, encourages prevention, and connects today’s complaint to yesterday’s history.

The convenient alternative solved a friction problem. It did not necessarily replace everything that was lost.

Health Professionals Pay Attention

The friction tax also falls heavily on health professionals.

A time-and-motion study published in Annals of Internal Medicine found that for every hour physicians spent in direct clinical face time with patients, they spent nearly two additional hours on electronic health records and desk work during the workday. Physicians also reported another one to two hours of personal time each night devoted largely to EHR tasks.

Some of that work is essential. Documentation protects patients. Medication reconciliation matters. Reviewing laboratory results matters. Safety checks matter.  The goal should never be completely frictionless medicine because some friction protects people from harm.

The problem is friction without corresponding value: entering information that already exists, moving data between systems that cannot communicate, clicking through low-value alerts or requiring highly trained clinicians to perform tasks that do not require their expertise.  How many times have you entered a doctor’s office and been greeted with a clipboard with papers on your medical history?

Every unnecessary minute has an opportunity cost. It is time unavailable for examining someone, explaining a diagnosis, listening to a family or simply looking another human being in the eye. When process begins consuming the relationship, efficiency has defeated its own purpose.

Families Have Become the Integration Layer

Another group quietly absorbs enormous friction: family and friend caregivers.

When organizations cannot coordinate, close connections often coordinate for them. They maintain medication lists, arrange appointments, call insurers, locate specialists, monitor portals, manage bills, and relay information from one clinician to another.

AARP estimated in 2026 that 59 million family caregivers provided 49.5 billion hours of unpaid care annually, work valued at approximately $1.01 trillion.

Not all of that time represents administrative friction. Much of caregiving is essential, personal and deeply human. Yet some portion exists because families have become the connective tissue between organizations and professionals that do not consistently connect.

We have created millions of unpaid care coordinators and rarely count their time as part of the cost of care.

Start Asking Who Pays

None of this is an argument against technology, utilization management or administrative oversight. Innovation can remove enormous amounts of friction. The challenge is determining whether it actually did.

Before introducing a new process or technology, health system innovators should ask: “How many steps does this remove? How many does it add? Whose time does it save? Whose time does it consume? What new work does it create? What happens to the person who lacks the time, digital skills, financial resources or family support to navigate it?”

Eventually, those questions should become measurable. They mean even push the fragmented health ecosystem to share and prioritize a common metric: patient and health professional experience.

Imagine evaluating innovation not only by clinical benefit and financial return but also by a friction score that measures time, clicks, handoffs, repeated information requests, administrative hours, delays, and work transferred to patients and caregivers.

A sick care system is not healed simply by adding more technology. It becomes healthier when innovation reconnects people, information and care rather than placing another obstacle between them.

The next great advance in health may not come solely from adding something new. It may come from finally recognizing the cost of everything we have already added. When a system saves itself time by consuming someone else’s, it has not eliminated cost. It has simply sent the bill to someone who cannot invoice it back.

The post The Hidden “Friction Tax” appeared first on Medika Life.

Scientists have known about this problem for years and are now speaking up more openly. Most drugs that pass animal testing still fail once they are tried in humans. Different studies report different numbers, but many put the failure rate above 90 percent. That means for roughly every ten drugs that look promising and safe in a mouse or a rat, only about one will end up helping a real patient. Some researchers say that number gets used out of context, since animal testing is meant to catch problems early, not guarantee a drug will succeed. Nearly everyone in the field agrees the gap between animal results and human results is real, and it is large.

This isn’t a small technical detail. It means patients wait longer for treatments. It means research money gets spent chasing drugs that would never work in people. And for conditions like cancer, Alzheimer’s, and other brain diseases, it may be one reason so few genuine breakthroughs have reached the people who need them most.

Why a Mouse Body Isn’t a Human Body

The core issue is that animals and humans, while similar, are not the same. A disease that shows up in a mouse doesn’t always behave the way it does in a person. Sometimes it doesn’t show up in the animal at all.

Matthias Zilbauer, a doctor and researcher at the Cambridge Stem Cell Institute, put it plainly: “A lot of human diseases either do not occur in animals or occur in a different way because they’re not human. We want tests and models that can tell us which treatments work, and in what patients, and a mouse cannot tell us that.”

A recent study from Stanford looked closely at why dementia treatments that work well in mice keep failing in human trials. The researchers found that most mouse studies test a drug early, before any real signs of disease appear. Human trials almost always involve people who are already sick. Giving a drug to a healthy mouse before a disease starts is a very different test than giving that same drug to a person who already has memory loss or brain damage.

The study also found that most mouse research only used male mice, which means treatments that might work differently in women were never properly tested to begin with. In this sex bias, it is something that, in the past, has been endemic in research, with most results reflecting work with males, not females.

None of this means animal research is worthless. It has led to real, life-saving treatments for vaccines, cancer, and countless other conditions. But it also means animal results have limits that haven’t always been discussed honestly, and those limits matter most for diseases we still don’t know how to cure.

New Tools Built From Human Cells

Because of gaps like these, researchers in the UK are now building tools made directly from human tissue instead of relying only on animals.

In Cambridge, scientists are growing tiny clumps of human organs, called organoids, using cells donated by NHS patients. These clumps, some smaller than a millimeter, can mirror how an actual organ behaves, including how it responds to disease and to new drugs. Researchers are starting with organoids for bowel diseases like Crohn’s disease and ulcerative colitis, along with organoids to study tumors and brain conditions.

Other researchers are building “organ-on-a-chip” devices, small devices lined with real human cells that mimic how a drug moves through the body. One company, VivoSphere, is growing heart cells in small gel spheres to catch dangerous drugs before they ever reach an animal or a patient. As the company’s Yuan Tian explained, “If something is going to fail, there’s a lower risk for the animals and also for the patients.”

The UK government has backed this shift with money and deadlines. Under a new national roadmap, regulatory skin and eye irritation testing on animals is set to end by the close of 2026. Botox strength testing on mice is expected to end by 2027, replaced by lab-based methods that don’t require a live animal at all.

By 2030, the government wants to sharply cut testing on dogs and primates that tracks how drugs move through the body. In total, the UK has committed 75 million pounds to build out these new methods and make it easier for researchers to get them approved for use.

The United States is moving in a similar direction. In 2025, the FDA announced it would begin accepting artificial intelligence models, advanced lab-grown tissue tests, and other non-animal methods in place of some animal studies, starting with a pilot program for a class of drugs called monoclonal antibodies.

Why Animals Still Matter, and Why This Isn’t Simple

None of this means animal testing is about to disappear, and it would be unwise to suggest otherwise. Under UK law, animals cannot be used in research if a working non-animal method already exists to answer the same question. But for many questions, that alternative doesn’t exist yet.

Wendy Jarrett, who leads the group Understanding Animal Research, made this point clearly: animals have been fundamental to the discovery of most medicines available today, and to treating disease in people and animals alike. Edith Heard, director of the Francis Crick Institute, said much the same, noting that animal research remains necessary for complex diseases like cancer and Alzheimer’s, even as her institute works to reduce and replace it wherever possible.

This is also, importantly, a question of animal welfare, not just scientific accuracy. Last year in Britain alone, 2.54 million animal testing procedures were carried out, most involving mice, rats, fish, and birds. A small percentage involved dogs, cats, horses, and monkeys. Reducing that number matters on its own terms, separate from whether animal tests are scientifically reliable.

Groups on both sides, from the RSPCA to the pharmaceutical industry, have welcomed the UK’s new roadmap, which suggests this is one of the rare issues where scientists, drug companies, and animal welfare advocates largely agree on the direction, even if they disagree on how fast to move.

What seems to emerge is not a choice between animals and no animals, but a more honest reckoning with what animal testing can and cannot tell us. As Dr. Juliet Dukes of the charity Replacing Animals in Research put it, tools built from real human tissue have the potential to deliver something animal testing never could: medicine built around the actual patient in front of a doctor, not just the mouse in the lab down the hall.

The post Nine Out of Ten Cures Never Reach You appeared first on Medika Life.

Its leaders were visible throughout the convention, participating in discussions on biopharma innovation, precision medicine, artificial intelligence, investment, genomics and policy. Partnership announcements emerged throughout the week. Delegations moved between panel discussions and private meetings with investors, entrepreneurs, researchers, and industry leaders. The message was clear. Abu Dhabi is making a strategic effort to become a notable player in biotechnology and the life sciences.

The timing is not accidental.

Around the world, governments increasingly view biotechnology as a strategic investment industry. Scientific innovation drives economic growth. Advanced therapeutics create new manufacturing opportunities. Genomics and precision medicine are reshaping approaches to disease prevention and treatment. Nations that attract talent, investment and scientific expertise position themselves at the forefront of one of the century’s most consequential industries and life-sustaining movements.

Abu Dhabi is determined to be among those countries.

Building the Innovation Foundation

Substantial investments and partnerships in infrastructure, research, education and health innovation support the Emirate’s ambitions.

In April 2025, Abu Dhabi launched the Health, Endurance, Longevity and Medicine (HELM) Cluster, an initiative designed to establish a globally competitive ecosystem spanning biotechnology, pharmaceuticals, medical technology, genomics, digital health, artificial intelligence and advanced manufacturing.

Officials project the initiative will contribute AED 94 billion to the economy by 2045, attract more than AED 42 billion in investment and create approximately 30,000 jobs.

Those figures reflect more than economic development goals. They signal a growing recognition that biotechnology is a cornerstone of future growth and global competitiveness.

The Emirate is not starting from scratch. Organizations including M42, PureHealth, Mubadala Bio, Khalifa University, and the Mohamed bin Zayed University of Artificial Intelligence have established a foundation that combines research, clinical capabilities, advanced analytics and investment resources. The UAE Genome Program has surpassed 900,000 sequenced genomes, making it one of the world’s largest population genomics initiatives and providing a valuable resource for scientific research and precision medicine.

These investments provide the ingredients necessary to compete. Partnerships provide the opportunity to accelerate progress.

Building Through Collaboration

Biotechnology has long been a collaborative enterprise among private equity and entrepreneurs, academic medicine and corporations, and, now, nations working side by side with other countries’ governments.

Scientific discovery depends on the exchange of knowledge among researchers, entrepreneurs, clinicians, manufacturers, regulators, and investors. No single country possesses every advantage. Successful ecosystems learn how to connect their strengths with those of others.

Abu Dhabi’s recent actions suggest its leaders understand this reality more than anyone else. They act on it.

During the BIO International Convention, the Department of Health – Abu Dhabi announced a strategic collaboration with Sanofi focused on vaccine development and life sciences innovation. The previous year at BIO in Boston, the Department established a partnership with Boehringer Ingelheim that expanded access to the company’s OpnME research platform, creating new opportunities for translational research and scientific discovery.

An additional 2025 agreement was signed with Abbott, focused on pharmaceutical innovation, manufacturing capabilities, and emerging technologies.

These were not isolated announcements. They represented a broader effort to connect Abu Dhabi with leaders across the global life sciences community. That strategy continued at BIO 2026.

On June 23, 2026, the Department of Health – Abu Dhabi announced a strategic partnership with Biocom California, one of the world’s largest life sciences associations representing more than 1,800 biotechnology, pharmaceutical, and medical technology organizations. The agreement creates a formal gateway between the California innovation ecosystem and Abu Dhabi’s growing life sciences sector, strengthening opportunities for collaboration among researchers, entrepreneurs, investors, and innovators across both markets.

The significance of the announcement extends beyond California. It reflects Abu Dhabi’s effort to connect itself to some of the world’s most influential innovation networks and to participate in the exchange of scientific knowledge, talent, and investment that increasingly defines biotechnology leadership.

Moving Up the Biotech Value Chain

If the Biocom agreement demonstrated Abu Dhabi’s commitment to global collaboration, a second announcement made the Emirate’s ambitions even clearer.

On June 24, 2026, the Department of Health – Abu Dhabi, M42, and Mammoth Biosciences announced a partnership to advance gene-editing therapies, clinical research, and advanced therapy manufacturing in Abu Dhabi. The agreement seeks to leverage insights generated through the Emirati Genome Program while supporting the development of next-generation treatments for inherited diseases.

This announcement stands out because it moves beyond ecosystem building and into the development of future therapies.

Mammoth Biosciences was co-founded by Nobel Prize-winning scientist Jennifer Doudna, whose pioneering work helped bring CRISPR gene-editing technology into medicine. Under the agreement, Mammoth will contribute its proprietary gene-editing platform, M42 will provide genomics, health, and clinical research infrastructure, and the Department of Health will support the regulatory and research environment needed to advance development.

The collaboration includes plans to introduce Mammoth’s lead clinical candidate, MB-111, into Abu Dhabi’s research ecosystem, support advanced gene-editing clinical trials, establish advanced therapy manufacturing capabilities, and develop local expertise through workforce training programs.

Perhaps most significantly, the partnership highlights how Abu Dhabi is leveraging its genomics investments. The Emirati Genome Program has created one of the world’s most comprehensive population genomics initiatives. The Mammoth agreement represents an effort to translate those insights into therapies targeting inherited diseases.

As H.E. Dr. Noura Al Ghaithi noted when announcing the partnership, Abu Dhabi is focused on translating genomic insights into therapies to address some of the most complex inherited diseases affecting populations in the region and worldwide.

Leadership Matters

The prominence of Abu Dhabi at BIO 2026 reflects sustained engagement from senior leaders. H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, and Dr. Mohamed Al Ameri, Division Director of Genome and Biobank at DoH, are among the officials representing the Emirate’s vision throughout the convention.

Their participation reflects a broader commitment. During Abu Dhabi’s 2025 strategic mission to the United States, approximately 40 representatives from 12 organizations attended more than 20 strategic meetings, conducted 16 institutional visits, participated in 9 BIO-related panels, and established 7 new partnerships and agreements.

Such activity underscores an important point. Building a biotechnology ecosystem requires more than investment capital. It requires leadership, patience, and a willingness to build relationships across borders and disciplines.

A Must-Watch Innovation Hub

For decades, discussions about biotechnology leadership have focused on a familiar collection of cities and regions. Boston, San Diego, Basel, London, and Singapore earned their positions through scientific excellence, entrepreneurial activity, and investment.

Abu Dhabi is pursuing a different path.

The Emirate is leveraging capital, scientific infrastructure, genomics, artificial intelligence, policy support, and international partnerships to establish a presence in the global biotechnology landscape. Its strategy recognizes that modern biotechnology advances through collaboration and that scientific leadership increasingly depends upon connecting talent, expertise, and resources across borders.

BIO 2026 demonstrated that Abu Dhabi is no longer simply expressing an ambition to participate in the life sciences sector. Through initiatives such as the HELM Cluster, partnerships with organizations including Sanofi, Boehringer Ingelheim, Abbott, Biocom California, and Mammoth Biosciences, and investments spanning genomics, research, and advanced therapies, the Emirate is laying the foundations for a biotechnology ecosystem with global aspirations.

Whether Abu Dhabi joins the ranks of the world’s leading life sciences hubs remains to be seen – but it should be watched closely. What is increasingly difficult to overlook is the depth of its commitment and the speed with which effort is being translated into action.

The post Abu Dhabi’s Biotechnology Ambition Comes into Focus at BIO 2026 appeared first on Medika Life.

Despite living longer than men, women spend approximately 25 percent more of their lives in poor health, according to research from the World Economic Forum and the McKinsey Health Institute. Across reproduction, brain health, autoimmune conditions, cardiovascular disease, and mental health, the gaps in research, funding, and care are persistent.

That reality provided important context for the launch of The Shift, a new mini documentary series from BBC StoryWorks Commercial Productions, unveiled at HLTH Europe. The series explores issues ranging from reproductive health and cardiovascular disease to autoimmune disorders, menopause, mental health and healthy aging. Through storytelling, the documentary project elevates the experiences of women while highlighting the challenges that persist and the opportunities for progress.

The HLTH EU panel discussion was timed for the opening of The Shift and featured Shahnoor Abbas, Senior Series Developer and Research Development Lead for The Shift at BBC StoryWorks Commercial Productions; Elena Bonfiglioli, General Manager, Global Health & Life Sciences at Microsoft, and Priya Agrawal, MD, Vice President, Global Health Equity and Partnerships at MSD. Their conversation, moderated by Jody Tropeano Greene, Head of Content for HLTH, explored why women’s health remains one of the most significant opportunities for innovation, investment and system improvement.

A Conversation Decades in the Making

The panelists approached the topic from different perspectives, yet a common theme emerged. Women’s health has received increasing attention for more than a decade, but many of the barriers women encounter remain rooted in the design of health systems.

For BBC StoryWorks, The Shift represents an effort to sustain attention on issues that too often receive episodic interest. The series combines personal stories with broader insights into the realities women face across different countries, cultures and stages of life.

The BBC initiative and the HLTH EU mainstage conversation arrive at a time when women’s health is attracting growing attention from investors, entrepreneurs, policymakers and health industry leaders. New companies are emerging. New technologies are being developed. More organizations are recognizing both the societal and economic importance of addressing longstanding gaps in care.

The timing of The Shift is notable. Women’s health innovation is receiving growing attention from investors, entrepreneurs, policymakers and health leaders. Industry analysts estimate that approximately $2 billion was invested in venture-backed women’s health companies across the United States and Europe in 2025, reflecting increased interest in addressing challenges that extend beyond reproductive health to include cardiovascular disease, menopause, mental health, oncology and healthy aging.

The trend signals growing recognition that improving women’s health is a societal imperative and a significant economic opportunity. Yet as the discussion at HLTH Europe made clear, investment and innovation alone will not be enough if women continue to face fragmented systems that are difficult to navigate.

When Access Exists but Navigation Fails

Dr. Agrawal, an obstetrician-gynecologist by training, whose work has included clinical practice in the UK NHS, global pharma brand stewardship in emerging middle-income nations, maternal health awareness initiatives, and the creation of sustainable health markets, described a reality familiar to many women. Access to care may exist on paper; however, reaching that care, understanding available options and navigating fragmented systems remains a challenge.

“We’ve built systems like mazes with different entry points, different providers and different messages,” said Dr. Agrawal. “Women are often left navigating all of this themselves at the moments where they are most vulnerable.”

Her observation echoed the comments by fellow panelists, which touched on an issue that extends beyond women’s health. Across many countries, patients frequently encounter disconnected providers, inconsistent communication and care journeys that require them to coordinate appointments, referrals and information on their own. The burden of connecting those pieces often falls on the individual seeking care rather than the system intended to support them.

For women, that complexity can be especially challenging. Responsibilities related to caregiving, work, family and personal health often intersect at the very moment care is needed. Understanding what symptoms are normal, knowing when to seek help, determining where to go and finding trusted sources of information become added obstacles.

That reality led to one of the discussion’s compelling observations. “This is not an access problem. It’s a design problem.”

The distinction matters. Discussions about women’s health often focus on whether services exist. Design asks a different question: can people realistically find, understand and benefit from those services when they need them most?

The Power of Stories to Sustain Change

The panel also explored the role technology may play in addressing those challenges. Rather than adding new layers of complexity, emerging digital tools and artificial intelligence applications are increasingly being developed to simplify navigation, improve continuity and support people between clinical encounters.

“What excites me is that technology is finally starting to reduce friction instead of adding layers of complexity,” Dr. Agrawal observed.

That perspective aligned with comments from Bonfiglioli, whose work at Microsoft focuses on helping health systems leverage data, cloud technologies and artificial intelligence to improve outcomes. Technology, however, was not presented as a solution on its own. The discussion repeatedly returned to the importance of human connection.

Those themes are central to the documentary series itself. BBC StoryWorks has built a reputation for transforming complex issues into compelling narratives that audiences can understand and relate to. Through The Shift, the goal is not merely to document challenges but to foster greater understanding of the experiences women face and the opportunities that exist to improve care.

Abbas emphasized the power of storytelling to connect data and lived experience. Statistics can identify a problem. Research can explain it. Stories help people understand why it matters and why action is necessary.

That may be the enduring value of The Shift. The series does not introduce a new conversation. Instead, it brings fresh perspectives to longstanding challenges. Through stories from around the world, the films remind viewers that behind every statistic is a person navigating the complexities of health and care. By fostering greater understanding and empathy, the series encourages health leaders, innovators and policymakers to view women’s health not as a periodic topic of interest, but as an ongoing priority deserving sustained attention and action.

The women featured throughout the series deserve more. The discussion at HLTH Europe reinforces that improving women’s health is more than developing new technologies and expanding services. It is also about creating systems that are easier to navigate, more responsive to people’s medical priorities and ultimately more human in their design.

The post At HLTH Europe, BBC StoryWorks Shines a Light on Women’s Health and the Challenge of Navigating Care appeared first on Medika Life.

Bringing Conversational AI to Scientific Research

The announcement arrives as artificial intelligence continues to reshape nearly every corner of the health sector. Much of the attention has focused on applications designed for consumers seeking information or clinicians seeking support in managing increasingly complex workloads. Briya is directing its attention to a different priority audience: medical researchers in academia, hospitals and life science companies.

The decision reflects a recognition that scientific inquiry often remains constrained by barriers that have little to do with science itself. Researchers routinely navigate fragmented data sources, technical requirements, analytical platforms and resource limitations before they can begin testing a hypothesis or exploring an observation.

The Next Step in Briya’s Evolution

Briya is executing on the established understanding that artificial intelligence can help reduce those barriers.

Researchers using AIRE will be able to explore public health information, including data from the U.S. Centers for Disease Control and Prevention, through a browser-based conversational interface. Rather than writing code, users can ask questions in natural language, refine their inquiry through dialogue and review the analytical pathway used to produce results.

“The last few years proved that AI can generate answers,” Briya co-founder and CEO David Lazerson told Medika Life. “The next challenge is making AI capable of generating trustworthy science. That requires a fundamental shift from general-purpose AI systems to research environments built around transparency, epidemiological methodology and scientific accountability.”

The announcement represents the latest step in Briya’s evolution. Founded in 2020 by Lazerson and Chief Technology Officer Guy Tish, the company initially centered efforts on helping organizations connect fragmented health data while maintaining privacy protections, governance requirements and institutional control over sensitive information.

Medical records rarely exist in a single location. Information is often distributed across electronic medical records, laboratory systems, imaging platforms, physician notes and institutional databases. Briya developed a federated approach that allows information to remain within source organizations while supporting approved research across participating data environments.

AIRE expands that mission from data access to data exploration.

The platform is designed to support cohort construction, endpoint validation, treatment pathway analysis, chart review and the exploration of structured and unstructured clinical information. Researchers interact with the platform through conversation rather than code, allowing them to start with a scientific question rather than a technical workflow.

The strategy mirrors an approach that has proven successful in other areas of artificial intelligence. Consumer platforms such as ChatGPT and Perplexity accelerated adoption by allowing users to experience the value of AI before deciding whether additional capabilities justified a subscription.

Reducing the Distance Between Questions and Answers

Briya is applying a similar philosophy to research. Many health technology companies continue to pursue adoption through enterprise purchasing processes, institutional pilots and lengthy implementation cycles. The Briya approach places the researcher at the center of the experience and allows investigators to determine the platform’s value through direct, frequent use.

The company believes that approach may be particularly meaningful for researchers working outside large academic medical centers and major pharmaceutical companies. Those institutions often have access to dedicated data science teams and sophisticated analytical resources. Smaller universities, physician-scientists, public health investigators and community-based researchers may not.

The absence of resources does not diminish the importance of the questions they seek to answer. In fact, as many attending HLTH EU head from Amsterdam to BIO International in San Diego, many of the biggest life-changing advances start in smaller research settings.

Giving Researchers a Seat at the Table

A physician observing an unusual treatment response, a public health researcher investigating a local health pattern, or an early-career investigator evaluating a new hypothesis all face the same challenge: transforming observation into evidence. That process frequently requires technical expertise and infrastructure that are not universally available.

Reducing those barriers could expand participation in research and potentially broaden the range of questions being explored. Accessibility alone, however, is not enough.

Scientific inquiry requires transparency, reproducibility and methodological rigor. Researchers must understand how conclusions are reached, what assumptions influence an analysis and where potential bias may exist.

A Move from Observation to Evidence

Recognizing those requirements, Briya recently appointed internationally recognized epidemiologist Professor Jonathan Samet, MD, MS, as Chief Epidemiologist. Dr. Samet is Professor of Epidemiology and Occupational and Environmental Health, and the former Dean of the Colorado School of Public Health.

“Scientific rigor and accountability cannot be layered onto AI after the fact,” Dr. Samet told Medika Life. “If these technologies are going to play a meaningful role in healthcare research, transparency, reproducibility and epidemiological methodology must be built directly into the system itself.”

Samet added that researchers need to understand more than an AI-generated conclusion: “Researchers need to understand not only what an AI system concludes, but how it reached those conclusions and what risks may exist along the way.”

His appointment reflects a broader challenge facing artificial intelligence in research environments. While generative AI systems can produce clear and persuasive responses, researchers and institutions must be able to evaluate the methods, assumptions and analytical pathways behind those outputs.

Trust, governance and cybersecurity have become as important as speed and convenience. Health information remains among the most sensitive categories of personal data. Institutions considering AI-enabled research environments must evaluate privacy protections, security controls and governance requirements alongside scientific capabilities.

Briya says its architecture is designed to allow data to remain within source organizations while supporting anonymization, compliance controls and auditable pathways for approved analysis.

Briya’s decision to open access to AIRE arrives at a time when researchers are under increasing pressure to produce meaningful scientific output while navigating growing volumes of health information. The platform’s no-cost entry point reflects a broader shift occurring across technology, where organizations increasingly recognize that adoption begins with customer experience. By allowing researchers to engage directly with data through a conversational interface, Briya is reducing barriers that have traditionally separated scientific questions from scientific exploration and adoption.

The announcement broadens the conversation surrounding artificial intelligence in health. Much of the industry’s attention has focused on consumer and clinical applications. Briya is directing attention to another critical constituency whose work influences every future therapy, diagnostic and public health intervention.

As HLTH Europe begins, the company is making the case that empowering researchers may represent one of the most consequential applications of artificial intelligence in health. If successful, the approach could help accelerate discovery, expand participation in research and provide investigators with a direct path from observation to evidence to implementation.

The post At HLTH Europe, Briya Opens No-Cost Access to AI-Powered Research appeared first on Medika Life.

A bill passed by the state legislature in March then signed into law by Democratic Gov. Jared Polis allows Colorado to further uncouple itself from federal guidance.

The law allows health officials to follow the recommendations of national medical groups when making decisions such as purchasing bulk vaccines for the Medicaid program.

“We are insulating our state from the dysfunction coming out of Washington,” said Democratic state Sen. Kyle Mullica, a co-sponsor of the bill and a registered nurse. “We’re going to rely on science.”

“From fighting during the pandemic for Coloradans to get vaccines as quickly as possible to combating the Trump Administration’s barriers to getting vaccinated, we have expanded access to vaccines for Coloradans who want them,” Polis said in a statement when he signed the law.

Colorado is one of at least 29 states that, along with Washington, D.C., have taken steps to bypass the new federal recommendations amid worries that the changes could chip away at public trust in vaccines and erode broad vaccine coverage.

Previously, Colorado, like most states, had followed federal guidance set by the Centers for Disease Control and Prevention. In January, CDC advisory panelists, selected by Health and Human Services Secretary Robert F. Kennedy Jr., removed six pediatric immunizations from the agency’s universal recommendation list.

Last year, doctors, scientists, local leaders, and other supporters came together to form an outreach and advocacy coalition called Colorado Chooses Vaccines.

The group aims to offer a clear, unified voice on the proven benefits of vaccines and reassure residents confused by the many federal changes.

Carol Boigon, a former Denver City Council member, joined the group because she wants more people to hear her own chilling story about vaccine-preventable illness.

“Every summer everybody got sick,” Boigon said, recounting her childhood in 1950s Detroit.

The illness was polio, a highly contagious viral disease that attacks the nervous system, sometimes causing partial or full paralysis.

During the summer of 1953, “the whole block was sick and some of us got crippled, and that was just the way it was,” she said.

New Group Steps Up

Boigon’s personal history will be part of the coalition’s work to educate new generations about the dangers of infectious diseases that were once common in the U.S. but are now relatively rare.

The group, which formed last September, will also compile vaccine information from medical groups and the state health department and advocate for policy proposals with the state government.

“It was in direct response to the federal threats,” said another coalition member, former state lawmaker Susan Lontine. She leads the nonprofit Immunize Colorado.

Another member, public relations specialist Elizabet Garcia, wants more outreach to Hispanics, whose vaccination rates lag behind other groups’.

“A lot of time it’s this fear that they’re going to have to pay out-of-pocket, that their insurance doesn’t cover it, that they might not even have insurance in general,” Garcia said.

Boigon was 5 when she got sick and was hospitalized for six weeks with a fever. The virus attacked her spine.

“None of my limbs worked immediately afterwards,” Boigon said.

Although she regained function in her other limbs, her right arm never fully recovered. She had to adapt, relearning everyday tasks such as reaching out to shake hands with people with her left hand.

In 1955, not long after she got sick, the new polio vaccine became more widely available to the public. As vaccinations took off, U.S. cases of polio, once one of the nation’s most feared diseases, dropped by an estimated 85%-90%.

Increasing Public Trust

State leaders have taken other steps to promote public health. After the Trump administration pulled the U.S. out of the World Health Organization, several states, including Colorado, decided to join the WHO’s Global Outbreak Alert and Response Network on their own.

Colorado also joined a multistate lawsuit challenging the Trump administration’s changes to the childhood vaccine schedule.

And the new state law has provisions besides allowing the state to diverge from federal recommendations. It codifies pharmacists’ ability to prescribe and give vaccines themselves. It also increases legal protections for healthcare workers who give vaccines.

“This law will provide more clarity to guide all Coloradans, including providers who administer vaccines,” Lontine said.

But the legislation has opponents who say it would interfere with parental choice and claim vaccines might be unsafe or ineffective.

“I just want to make sure we’re not just getting into a big political dispute between the federal recommendations — the CDC and so forth — and different political views in Colorado here,” said Republican state Sen. John Carson, who voted against the vaccine bill.

NPR contacted the U.S. Department of Health and Human Services about Colorado’s new law. Spokesperson Emily Hilliard answered in an email: “The updated CDC childhood schedule continues to protect children against serious diseases.”

Preventable Illnesses Surge

The flurry of statewide activity comes as Colorado and the nation have seen surges in illnesses such as flu and measles.

As of mid-May, Colorado had recorded 22 measles cases this year. In 2025, it registered 36 cases, according to the state health department, far surpassing totals from previous years.

Across Colorado, kindergarten vaccination rates for measles were 88% last school year — with only a few counties achieving rates of 95%, the level needed for herd immunity, according to data published by The Washington Post in December.

This has also been Colorado’s worst flu season in recent years.

Vaccination rates for both flu and covid-19 have dropped slightly in Colorado, according to the state health department.

Eight children in Colorado have died this season from flu; one from covid; and one from RSV, or respiratory syncytial virus. Vaccines for all three are available for children and recommended by the state’s health department.

Kennedy, a longtime anti-vaccine activist, has defended his decisions to overhaul the recommended schedule for childhood vaccinations.

In March, a federal judge put on hold many of the changes.

“We’re not taking vaccines away from anybody. If you want to get the vaccine, you could get it. It’s going to be fully covered by insurance just like it was before,” Kennedy told CBS News in January.

When a reporter suggested the new changes could result in fewer people getting a flu vaccine, Kennedy said: “Well, that may be, and maybe that’s a better thing.”

Boigon is sometimes incredulous at everything that has happened.

“It’s like we’re going backwards,” she said. “It’s like we have decided we don’t want a modern life; we want to be back in the 1950s, where children are sick and dying.”

This article is from a partnership with Colorado Public Radio and NPR.

The post Colorado Charts Its Own Course on Vaccines Amid Federal Pullback appeared first on Medika Life.

Despite this extraordinary pace of innovation, something fundamental remains broken. Patients still struggle to navigate care. Physicians continue to wrestle with fragmented systems, administrative overload and technologies that often add work rather than reduce it. Health innovators repeatedly introduce sophisticated tools into environments overwhelmed by operational complexity, lack of governance, cybersecurity concerns, workflow disruption and communication gaps.

The issue is no longer whether innovation benefits care. The issue is friction.

Consumers compare health care experiences to every interaction in daily life. They compare health care to Apple, where design simplifies complexity, to Amazon, where communication is continuous and immediate, and to banking and travel platforms providing real-time updates and seamless transactions. Some may even compare it to Domino’s Pizza, which promises delivery within 15 minutes or the pie is free. Expectations surrounding responsiveness and convenience have fundamentally changed.

Then they enter health care environments where forms are repeated, portals fail to communicate, prior authorizations delay treatment and updates disappear into silence. Patients are left to navigate disconnected systems during moments of vulnerability. The expectation gap between consumer and health care experiences continues to widen and increasingly shapes reputation.

In Healing the Sick Care System: Why People Matter, the observation is made that “Health care isn’t failing because we lack innovation. It’s failing because the system around that innovation has calcified.” The statement remains painfully real because innovation alone does not create confidence. Experience does.

Patients Remember the Journey, Not the Molecule

The patient and physician experience is shaped less by what a product promises and more by what happens after that promise enters real life. A medicine may be clinically meaningful, yet the experience surrounding it can still become exhausting if coverage is difficult to secure, prior authorization is confounding, specialty pharmacy coordination is slow, follow-up instructions are unclear or support programs require patients to become navigators of their own care.

In those moments, people are not judging science on its own merits. They are judging the total experience of trying to make that medicine or care available and understandable.

Physicians face their own administrative version of friction. A therapy may be medically appropriate, yet before treatment can begin, office staff must determine coverage, complete documentation, respond to payer step-through requirements, manage rejection appeals and explain delays that were never created in the exam room. Every additional administrative step consumes time, stretches staff and places additional strain on the physician-patient relationship. Even non-medical formulary changes can force physicians to restart conversations, explain unexpected medication switches and reestablish patient confidence in treatment decisions already made.

Patients remember counting the hours as they waited for answers. Physicians remember losing uncompensated time navigating systems and approvals. Nurses remember caring for patients through computer screens while typing notes into laptops on rolling carts in crowded hallways. Office managers remember the relentless cycle of paperwork, rejected claims, disconnected portals and endless callbacks trying to move care forward.

The therapy may eventually do its job, yet the pathway becomes inseparable from the memory associated with the brand, the company and the broader health care system. Every new process, technology and treatment promises improvement. For patients and health professionals, however, if the path to care feels uphill, the friction surrounding the experience can overshadow the value of the benefit.

For many patients, repeated uncertainty, delays and administrative obstacles contribute to a form of medical PTSD, where anxiety surrounding the system becomes inseparable from the treatment experience. For health professionals, the constant burden of navigating fragmented systems, managing approvals and compensating for communication gaps has become a leading contributor to burnout.

Friction is rarely remembered as an operational issue inside organizations. Patients and physicians experience it personally. This is why communication must be elevated operationally within health care. Communication is not marketing layered onto innovation after development is complete.

Health care organizations often think they are going through the process of delivering a product, therapy or platform. Patients and physicians experience something more personal: time invested in every interaction surrounding the innovation is time lost forever.

Health Technology Cannot Create More Work

The same reality applies to health technology startups and digital health innovators. Technological advancement alone does not guarantee adoption within health care environments already burdened by operational complexity and workforce fatigue.

Health care organizations do not merely evaluate whether technology works. They evaluate whether it integrates with existing workflows, whether cybersecurity standards are state-of-the-art, whether onboarding is manageable, whether interoperability gaps create additional burdens, and whether the institution can trust the accuracy of data.

Every additional step is a friction point, while every unresolved operational issue becomes part of the patient and physician experience surrounding the journey.

A sophisticated AI platform that requires clinicians to validate outputs continuously adds cognitive burden. A monitoring platform generating clinically important alerts contributes to fatigue. A system that requires extensive retraining or manual workarounds may succeed in demonstration but stumble in real-world conditions.

Innovation may arrive elegantly designed; however, it enters health care environments already strained by workflow complexity, disconnected systems, cybersecurity demands and administrative fatigue. The operational realities surrounding implementation often become as important as the innovation itself.

That reality does not diminish the importance of continuous invention. It reinforces the importance of implementation, communication and operational design within real-world clinical environments.

This shift is increasingly visible across the global health innovation marketplace itself. At HLTH Europe 2026, conversations are moving well beyond excitement surrounding artificial intelligence, digital therapeutics and next-generation platforms. The agenda sessions focus on interoperability, workflow integration, governance, patient engagement and operational implementation. Conference themes repeatedly emphasize connected systems, coordinated experiences and technologies that reduce fragmentation rather than add to a growing list of patches.

One of the more revealing themes from HLTH Europe focuses directly on interoperability and the longstanding frustration surrounding disconnected systems. The conference site notes that clinicians continue spending enormous energy managing platforms that fail to communicate effectively with one another. At the same time, artificial intelligence is increasingly viewed not as a replacement for care, but as a bridge helping systems “finally speak the same language.”

Another major focus involves provider realities. HLTH Europe speakers highlight workforce fatigue, cyber risks, operational strain and workflow challenges facing clinicians and health systems across Europe and beyond. These agenda themes reinforce a growing recognition throughout the industry that innovation cannot succeed if it increases the burden for the people expected to use it every day.

Health professionals increasingly describe a workplace dominated by more screens, more alerts, more documentation and less time with patients. Technology interrupting workflow rather than integrating into it creates resistance, regardless of how advanced the platform may appear. The hidden work behind implementation often becomes the defining experience for the people expected to use the system every day.

Cybersecurity provides another important example. Health professionals and patients may never fully understand the technical architecture protecting health information, yet they absolutely understand the emotional consequence of uncertainty surrounding data privacy, reliability and trust. Confidence in health technology is not built solely through functionality. It is reinforced through consistency, service, transparency and confidence that information is accurate, protected and responsibly governed.

Communication plays an equally important role here. If clinicians are left uncertain about updates, system changes or data governance responsibilities, confidence weakens. If patients do not understand how information is protected, trust erodes, regardless of how advanced the technology.

Communication remains inseparable from the care experience.

The organizations most likely to lead the future of health care will not distinguish themselves solely through technological achievement. They will reduce friction around the user interface, workflows and data accuracy.

The Companies That Win Will Simplify Complexity

This reality explains why access organizations such as Hims & Hers Health and Cost Plus Drugs deserve careful study from across the health care sector, regardless of whether industry leaders agree with every aspect of their business models. These organizations are built around reducing friction in how people access and experience care.

Their importance extends beyond convenience or pricing. These companies recognize that many traditional health institutions have underestimated: people increasingly expect health care experiences to reduce anxiety, simplify decision-making and provide continuity throughout the care journey.  They are “Amazon-like,” offering a “Buy It Now” simple click medical oversight option.

The rise of concierge medicine, direct-to-consumer health platforms and walk-in clinics with reduced wait times reflects a broader market signal the health sector cannot ignore. Patients are increasingly gravitating toward experiences where communication is clearer and access is more immediate.

For those able to afford concierge care, the attraction often extends beyond physician access itself. Patients value responsiveness, shorter wait times, easier scheduling, follow-up communication and the sense that someone is helping coordinate their journey through the system. Walk-in clinics and urgent care centers appeal for similar reasons. People are searching for environments where care is readily accessible, understandable and administratively manageable. The downside of loss of care continuity is offset by immediacy, which is what the consumer values most.

This migration reflects frustration with friction embedded throughout the trending health care experience. Long hold times, delayed callbacks, countless portals, disconnected records, repeated paperwork on clipboards and uncertainty surrounding next steps all shape how people perceive quality of care.

Communication once again sits at the center of the experience. Patients rarely separate operational snafus from expert care. They experience the entire journey as one connected reality – positive or negative.

The lesson is not that health care should behave exactly like retail commerce. Medicine carries ethical, scientific and regulatory responsibilities far beyond consumer transactions. Nevertheless, the operational expectations consumers now bring into the setting have changed.

People increasingly expect health care to be as responsive as the communication they experience elsewhere in life. Is that expectation reasonable?

The pharmaceutical industry, payers, providers, and health technology innovators must recognize that they no longer own just the patents on therapies, platforms or services. They also own the surrounding user experience.

Patients experience health as a continuous journey, not a “build your own adventure” exercise in navigating fragmented systems. Most people enter the system anxious and seeking reassurance from their health professionals. A delayed approval, clinically sterile information delivered through a diagnostic portal or a physician struggling to navigate complexity alongside them deepens that burden. These experiences shape how health care is remembered more powerfully than advertising campaigns or corporate positioning statements.

Those experiences ultimately shape reputations.

The future winners in health care will not simply develop innovative products. They will reduce friction around the human experience surrounding those products. They will recognize that communication, workflow design and responsiveness are not secondary considerations attached to innovation. They are part of the experience.

Patients and physicians rarely remember the elegance of molecular or system architecture behind a therapy or platform. They remember whether the experience made care delivery easier and more humane during moments that mattered.

The post Health Innovation Has a Friction Problem appeared first on Medika Life.

That is what makes the Digital Health & AI Innovation Summit (DHAI), taking place June 8-9 in Boston, distinctive within an increasingly competitive field of AI and innovation conferences. The Summit certainly offers a high-caliber program and noted speakers. However, its real value proposition beyond the agenda lies in the conversations and takeaways.

The carefully curated forum, organized by Amir Lahav, PhD, and World BI, is intentionally designed for a smaller community of roughly 500 attendees and more than 150 speakers and innovators. The result is that the connections become as valuable as the presentations.

That distinction matters more than many realize.

Artificial intelligence and digital health are moving at extraordinary speed. Health systems, pharmaceutical companies, regulators, investors and technology innovators are all trying to answer the same questions: How do we apply innovation responsibly while improving outcomes for patients and clinicians? How do we integrate AI into the R&D process? How can we leverage information technologies to accelerate the recruitment of the right people for clinical trials? The challenge is no longer simply technological capability. The challenge is implementation, governance and integration into the realities of care delivery.

Those questions are difficult to answer from the back row of a ballroom.

They are more likely to be explored over coffee between sessions, during a shared meal, or in quieter moments when people can challenge assumptions, exchange experiences and discuss what is actually working in health systems, research environments, and patient care settings.

That is where DHAI distinguishes itself.

The Power of Curated Expertise

What gives a conference enduring value is not only the quality of its speakers, but whether those speakers remain accessible enough to challenge assumptions, answer difficult questions and engage in unscripted dialogue. That is increasingly uncommon in modern health conferences, where influence often feels managed from a distance.

At DHAI, the proximity to the experience of 150 presenters is intentional.

The next era of health won’t be built in silos and it certainly won’t be forged by focusing on the hype. It requires leaders willing to share their failures alongside their successes, and their fears alongside their visions,” shares Amir Lahav, PhD, curator and DHAI organizer. “The DHAI Summit provides an exclusive, trusted space for these unfiltered conversations that rarely happen on public stages. This is an exclusive invitation to join the health AI  pioneers who are moving the needle and step into the room where the real trajectory of medicine is being shaped,” he adds.

For attendees seeking to understand how artificial intelligence is moving from experimentation to clinical reality, few conversations may prove more valuable than those surrounding the work of Dr. Dennis Wall at Stanford University. His groundbreaking efforts to apply AI to accelerate diagnostics, particularly in neurological and developmental conditions, reflect the growing intersection of machine learning and patient-centered medicine. In most settings, hearing someone like Wall speak might last 20 minutes. Here, the opportunity to continue the discussion between sessions may be equally important as the presentation itself.

The same can be said for leaders shaping the future of pharmaceutical innovation through AI. Thomas Fuchs, Chief AI Officer at Eli Lilly and Company, operates at the center of one of the most significant transformations underway in life sciences. His work integrating AI, pathology and drug discovery reflects how computational science is redefining therapeutic development. With pharmaceutical companies investing billions into AI-enabled research ecosystems, the ability to exchange perspectives directly with someone navigating those realities daily carries extraordinary value.

Precision medicine also takes on a more practical dimension through leaders such as John Axerio-Cilies, Chief Data and Technology Officer at Tempus AI. Tempus has become emblematic of how data science, oncology and artificial intelligence are beginning to reshape personalized medicine and diagnostics. Yet the real insight often comes not from keynote slides but from candid reflections on implementation challenges, physician adoption, workflow integration, and trust in AI-driven systems.

What also distinguishes the program is its recognition that health innovation no longer lives within traditional boundaries. Biology, computational science, organizational leadership and entrepreneurship are rapidly converging, creating entirely new expectations for how innovation enters the health ecosystem.

That reality becomes especially clear when considering trusted voices such as Tom Lawry, author of Hacking Healthcare and one of the most respected global advisors on AI strategy in health. For years, Lawry has argued that artificial intelligence alone cannot transform the delivery of care. Institutions themselves must evolve alongside technology. Leadership structures, workflow, culture and decision-making all become part of the innovation equation. His perspective reinforces an increasingly important truth: AI implementation is not fundamentally a technology challenge. It is a human challenge.

That same intersection between innovation and execution is reflected in the participation of Sally Ann Frank, Global Lead for Health & Life Sciences at Microsoft for Startups. Her work focuses on helping emerging companies move beyond promising ideas toward scalable and commercially viable solutions. Through strategy development, technical enablement and go-to-market support, she works directly with startups navigating the increasingly complex realities of AI, digital health and life sciences innovation. At a time when thousands of companies are entering the AI marketplace, Frank brings an unusually practical understanding of what separates experimentation from sustainable impact across the global health ecosystem.

The scientific and technical dimensions of the Summit are equally compelling. Arturo Loaiza-Bonilla, MD, MSEd, Co-Founder and Chief Medical AI Officer of Massive Bio, Network Chief of Hematology and Oncology at St. Luke’s University Health Network, whom I met recently during HITLAB Health Innovation Week in New York, champions an important evolution in medicine, where clinical leadership, oncology, data science and AI innovation are interconnected. His work sits at the intersection of precision medicine, clinical trials and responsible AI application, demonstrating how technology can expand access and support informed care decisions while keeping physicians and patients at the center of the experience.

The program also grounds innovation in the realities of patient care and health system operations. Through her leadership at NYC Health + Hospitals, Dr. Komal Bajaj has focused extensively on quality, equity and implementation within one of the nation’s largest public health systems. Her perspective introduces an important layer of realism into discussions that can sometimes become overly theoretical. AI may promise efficiency, but health systems must still ensure that innovation improves care delivery rather than complicates it.

That balance between aspiration and practicality is also reflected in leaders such as Lauren Li of Novartis, whose work in AI and innovation strategy demonstrates how global life sciences companies are integrating AI responsibly across research, development, and commercialization. The questions facing companies like Novartis are no longer whether AI will shape health innovation, but how to apply it responsibly while preserving scientific rigor and public trust.

Equally important to the DHAI agenda is the presence of Jeremy Walsh, Chief AI Officer at the Food and Drug Administration. At a moment when AI is moving rapidly into research, clinical decision support, diagnostics and operational health systems, regulatory leadership must provide oversight. FDA voice addresses a growing concern that innovation and governance cannot operate on separate tracks. The future of AI in health will depend not only on technological capability, but on transparency, accountability and safety. His perspective brings a policy and regulatory dimension to a conversation too often dominated by technology.

Taken together, these leaders represent more than expertise. They reflect the convergence of medicine, data science, biotechnology, health systems, patient engagement and policy. The global health ecosystem is entering a period in which barriers between disciplines are dissolving. Clinicians must understand data science. Technologists must better appreciate patient experience and the realities of workflow. Pharmaceutical leaders must think beyond molecules toward digital ecosystems and longitudinal patient engagement.

Why Human Connection Still Matters in the AI Era

That convergence changes the value of gatherings like this one. Large conferences often showcase these worlds side by side. Smaller curated forums create the possibility for those worlds to interact.

That dynamic is particularly important in digital health, where enthusiasm can sometimes outpace evidence. AI is neither a miracle nor a menace. It is a tool shaped by human intention, data quality and leadership. The most important conversations in AI and health today are not only about capability. They are about judgment.

How do we reduce physician burnout without depersonalizing medicine? How do we use predictive analytics responsibly? How do we ensure that innovation improves access rather than deepens disparities? How do we maintain trust while integrating increasingly autonomous technologies into patient care?

Those are conversations that require candor and mutual learning.

As someone attending and stepping to the stage during DHAI, I believe that may ultimately become its greatest differentiator. In health, relationships still matter. Communication still matters. Shared perspective still matters. Technology may accelerate insight, but human interaction remains essential to wisdom.

Health innovation does not advance through presentations alone. It advances through collaboration, challenge and conversation. Those exchanges between sessions often become the catalyst for strategies and unexpected ideas that continue long after this event comes to a close.

In a global health environment often defined by complexity, there is growing value in spaces where innovation feels ambitious and human. The DHAI appears designed to deliver that ROI.

The post The Value of Health AI Conferences Is No Longer the Stage. It’s the Hallway Conversation appeared first on Medika Life.

An operational model developed in Algeria may show a way that countries can make childhood vaccines more effective, more acceptable and more economical. It is a model that may provide a framework for middle-income countries across the globe, including many across the rest of Africa.

Six-in-one (or hexavalent) vaccines are cutting the number of clinic visits needed to prevent multiple life‑threatening infections and easing pressure on already stretched health systems. Growing economic evidence from Algeria and several Latin American countries suggests that while these vaccines may cost more upfront, the investment may be largely or entirely recovered through fewer appointments, streamlined logistics, and a reduction in cases of vaccine-preventable diseases and potential adverse events from vaccination. Yet the children who could benefit most – those living in low‑ and middle‑income countries are still the least likely to receive them, widening an avoidable gap between what modern vaccines can do and the protection children actually receive.

Most hexavalent vaccines save money in another way: they reduce the number of adverse events – side effects – that require treatment in a hospital or clinic. Acellular hexavalent vaccines include a type of protection against pertussis, or whooping cough, which is the gold standard for immunization in higher-income countries but has not yet been widely adopted beyond them.

With more than a decade of historical data supporting safety and efficacy, these acellular pertussis vaccines have a notable track record of improving vaccination coverage rates (VCR) and parents’ willingness to have their children protected, as they cause fewer painful adverse events [1].

Acellular pertussis (aP) vaccines are formulated using isolated antigens, which are purified and detoxified, thereby removing most of the components of the bacterium that cause undesirable reactions [2].

Most low- to middle-income countries still use whole-cell pertussis vaccines, which include a suspension of the entire inactivated Bordetella pertussis organism – some 3,000 antigens. Although the inclusion of far more antigens can result in a marginally higher immune response, the complexity of the vaccine leads to varying amounts of reaction-causing components between batches of vaccine and varying levels of protection [2].

The combination of more adverse events and variable efficacy means that developing countries bear a disproportionate share of the burden incurred through side effects. The side effects in children lead to an increased reluctance among parents to agree to future vaccines for their children and higher costs for the healthcare system. These problems often arise in healthcare systems that are inadequately equipped to deal with them.

Expert opinion from Algeria indicates that acellular hexavalent vaccination has improved vaccination coverage levels and simplified the vaccination schedule by reducing the number of appointments. It reduces the required number of immunization visits from ten to six. This eases pressure on overstretched health services, simplifies logistics and cold-chain management, and reduces indirect societal costs, including the time parents spend away from work.

Algeria is the third WHO African region country to adopt the acellular hexavalent vaccine into its national immunization schedule. Economic data from those countries and several in Latin America demonstrate that a rollout of the vaccine across African countries is not only possible but also economically advantageous [3,4,5,6].

Algeria’s vaccination metrics: an operational model for success

Vaccines have transformed child health in Algeria, as they have across the world. Since the initial introduction of vaccination in Algeria, followed by sustained efforts to expand the vaccination schedule, infant mortality rates have dropped dramatically from 163 per 1,000 live births in 1966 to 20 per 1,000 in 2023, a reduction of around 87% [7].

The percentage of children protected in Algeria has exceeded the targets set by the World Health Organization (WHO) for decades, with diphtheria, tetanus toxoid and pertussis (DTP) coverage consistently above 90% [8]. As in many countries, the COVID-19 pandemic disrupted healthcare systems, leading to a decline in vaccination rates, with DTP-3 coverage, a key measure of childhood vaccination, reduced to 77% in 2022 [9]. This situation was quickly improved, with coverage increasing to 92% by 2024 [9].

In 2022, three cases of polio caused by circulating vaccine-derived poliovirus type 2 were reported [10]. Rarely, the circulating vaccine-derived virus causes polio, highlighting the necessity of timely vaccination with IPV, with which these vaccine-derived cases do not occur [11].

The shift to hexavalent vaccination

Algeria’s shift from its former schedule to hexavalent vaccination was not a straightforward process. Initially, the five-in-one (or pentavalent) vaccine was replaced by a combination of the tetravalent vaccine (DTP-Hib) and the monovalent Hepatitis B vaccine (HBV), administered across 10 separate healthcare visits, necessitating additional appointments [12].

The change in the vaccination schedule resulted in delays in dose administration and a decrease in vaccination coverage. This issue was resolved with the introduction of the new schedule, which integrated an acellular hexavalent vaccine in 2023, reducing the number of required healthcare visits to six [13].

While polio vaccination was present in the previous schedule (with one IPV dose at 3 months and 3 OPV doses at 2, 4, and 12 months), inclusion as part of a hexavalent vaccine simplified the schedule (giving three doses of IPV at 2, 4, and 12 months associated with three OPV doses), helping to maintain the global strategy for polio eradication. The WHO recommends that all countries using OPV adopt a vaccination schedule with at least two doses of inactivated vaccine, which gives individual protection without the risk of vaccine-related polio [14].

The financial metrics of the switch

A recent whitepaper conducted a pharmacoeconomic analysis of the budgetary impact of transitioning from a whole-cell tetravalent vaccination schedule to an acellular hexavalent schedule. While the switch was associated with an increase in annual program expenditure of approximately 26 million Euros (around a 58% rise in upfront costs), this was substantially offset by nearly 19 million Euros in annual savings generated through the management of adverse events, improved logistics and transportation, and increased parental productivity [13]. Overall, roughly 73% of the upfront cost was offset by these savings.

Algeria is the latest in a series of examples where this is the case. The nominal, upfront cost of acellular hexavalent vaccines is typically higher than that of whole-cell vaccines; this has, in many cases, deterred countries from adopting them. However, there are many benefits at both the economic and systemic levels that recoup much of the costs of acellular hexavalent vaccines. In many instances, these costs are hidden and not factored into initial value calculations.

Similar experiences have been seen in other countries. In Argentina, Peru, and South Africa, the switch to hexavalent vaccines led to higher initial costs, but these were substantially offset by savings from fewer adverse events, lower programmatic expenses, and improved logistics. For example, in data from Argentina, roughly 90% of the initial investment into acellular hexavalent vaccines was recovered through fewer adverse event-associated costs and lower programmatic costs [15]. Peru reported a reduction in logistical costs by nearly 60%, with roughly 44% of the initial increase in costs recovered [16]. South Africa achieved overall savings of about 10 USD per child [3].

These calculations overlook benefits that are more difficult to quantify. For example, what costs are generated because of vaccines missed and infections caused by increased vaccine hesitancy on the part of parents. Across these settings, the higher upfront investment in hexavalent vaccines has proven to be economically viable, with much of the cost recouped through broader system efficiencies.

Programmatic benefits of hexavalent vaccination

Hexavalent vaccination offers the potential for simpler systems and higher levels of acceptance among patients. For the child, integrating six antigens into a single injection drastically reduces the number of needle sticks, alleviating injection-related anxiety and the prevalence of local reactions. This increases parental acceptance and helps to improve vaccination coverage.

Parents are relieved of the burden of coordinating multiple medical appointments, covering travel costs, and dealing with lost workdays. By reducing parental anxiety and the strain of repeated visits, combined vaccines help mitigate vaccine hesitancy within communities. This has been demonstrated in multiple studies across Africa, with investigations in Gambia and South Africa documenting concerns among parents about a child receiving more than two injections in a single visit [17,18]. Limiting the number of healthcare visits is also a crucial factor in increasing vaccine coverage in areas with limited healthcare infrastructure, such as those in rural southern Algeria.

For healthcare professionals, particularly in resource-limited settings such as rural areas in Africa, the adoption of combined vaccines helps to ease the administrative burden of multiple appointments. These formulations optimize consultation efficiency by drastically reducing the required administration time and simplifying inventory management [19].

The use of ready-to-use liquid vaccines, such as the hexavalents, has been shown to simplify and enhance the safety of the vaccination procedure when compared to vaccines that come as a powder that has to be reconstituted [20]. The preference for this approach among frontline workers is overwhelming: one study indicated that 97.6% of healthcare providers favored these liquid, combined formulations in their daily work [21]. Evidence supports this preference, demonstrating that the switch led to a dramatic reduction in administration errors (from 42.8% to 4%) and needlestick injuries (from 42.3% to 9.5%), while also yielding an average time savings of 1.1 minutes per dose [22].

The case for Hexavalent vaccination across Africa

Across the WHO Africa region, VCR has improved significantly over the last few decades; however, unfortunately, this improvement has stalled. The level of coverage for the third dose of DTP-containing vaccines, a standard benchmark for immunization system performance, has sat in the mid-70s for over a decade, with a current coverage of 76% [23].

This stagnation of the VCR is reflective of the ongoing issue of inequality. The gap in vaccine access runs not only between Africa and higher‑income regions, but also within the continent itself, where some countries consistently outperform others. Diseases, however, do not recognize borders; any outbreak that affects one country is likely to increase the risk to surrounding countries. Air travel enables a disease case to be spread to virtually any country in the world within just two days [24].

The COVID-19 pandemic was a clear example of the rapid spread in today’s world. Within a period of weeks, the virus spread from its origin in China to the entire globe, despite public health measures and lockdowns. With this in mind, any country that is falling behind on vaccination coverage becomes a weak link in a global chain where diseases can flourish and form reservoirs of cases that can allow diseases such as polio to spread unchecked.

Bringing vaccine equity to lower- and middle-income countries is therefore vital to addressing global health concerns. Hexavalent vaccination has demonstrated its ability to increase vaccine coverage in these countries. Among the WHO Africa region, Mauritius, which adopted hexavalent vaccination in 2017 [4] currently stands notably above the average for the region, with 96% coverage for the first dose of inactivated polio vaccine, and 93% for the benchmark based on DTP-containing vaccines [25].

Vaccine coverage translates into increased prosperity. Vaccination cannot be viewed as an inconvenient expense but as an investment. The WHO estimates that for every dollar spent, vaccination can yield a return on investment of around 54 USD – provided, of course, that the vaccines actually find their way into the arms of children [26].

As the Algerian case study demonstrates, higher upfront costs for acellular hexavalent      vaccines are often paid back by improvements in logistical efficiency, reduced healthcare burdens, and improved parental compliance. By bridging the gap between high- and low-income immunization standards through this investment, the life-saving benefits of gold standard vaccinations can become more than a privilege of geography, but a universal foundation for human health.

[This consensus paper is based on the findings of a white paper discussing the findings of a group of vaccination experts focusing on paediatric immunisation, supported by Sanofi. Intended for professional use.]

Reference list

1. Boisnard, F., Manson, C., Serradell, L., & Macina, D. (2023). DTaP-IPV-HB-Hib vaccine (Hexaxim): an update 10 years after first licensure. Expert Review of Vaccines, 22(1), 1196–1213. https://doi.org/10.1080/14760584.2023.2280236
2. World Health Organization (2017) The immunological basis for immunization series: module 4: pertussis, update 2017. Available at: https://www.who.int/publications/i/item/the-immunological-basis-for-immunization-series-module-4-pertussis-update-2017
3. Batson A, Glassman A, Federgruen A, et al. The world needs to prepare now to prevent polio resurgence post eradication. BMJ Global Health. 2022;7(12):e011485. doi: https://doi.org/10.1136/bmjgh-2022-011485
4. ReliefWeb. Hexavalent vaccine: less injections and more protection babies. Available at: https://reliefweb.int/report/mauritius/hexavalent-vaccine-less-injections-and-more-protection-babies
5. Olivera, I., Grau, C., Dibarboure, H. et al. Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine. BMC Health Serv Res 20, 295 (2020). https://doi.org/10.1186/s12913-020-05115-7
6. Romero M, Góngora D, Caicedo M. Cost-Minimization and Budget Impact Analysis of a Hexavalent Vaccine (Hexaxim®) in the Colombian Expanded Program on Immunization

Value in Health Regional Issues, 2021; 26, 150-159

7. World Bank Data. Available at: https://data.worldbank.org/indicator/SP.DYN.IMRT.IN?locations=DZ
8. World Health Organization. Immunization data: African region. Available at: https://immunizationdata.who.int/dashboard/regions/african-region/DZA
9. World Health Organization.  DTP vaccination coverage. Available at: https://immunizationdata.who.int/global/wiise-detail-page/diphtheria-tetanus-toxoid-and-pertussis-(dtp)-vaccination-coverage?CODE=DZA&ANTIGEN=DTPCV3&YEAR=
10. GPEI – Algeria. Available at https://www.archive.polioeradication.org/where-we-work/algeria/
11. Global Polio Eradication Initiative. GPEI-OPV. polio global eradication initiative . Published 2016. Available at: https://polioeradication.org/polio-today/polio-prevention/the-vaccines/opv/           
12. Practical Implementation Guide for the 2016 National Immunization Schedule in Algeria. Available at: https://cnpm.org.dz/wp-content/uploads/2024/01/Guide_Pratique_de_Mise_en_Oeuvre_du_Nouveau_Calendrier_Natio-1.pdf
13. Laichour A, Kihel M, Aissaoui A, Olivera G. Pharmacoeconomic evaluation of national immunization program realisation in Algeria: cost-minimization analysis of switch from DTwP-Hib + HBV + IPV to an acellular hexavalent (DTaP-HBV-Hib-IPV) vaccine. Poster presented at: ISPOR Europe 2023; November 2023; Copenhagen, Denmark. Value in Health. 2023;26(Suppl 2):S2-EE134.
14. WHO Polio Position Paper 2022. Available at: https://www.who.int/publications/i/item/WHO-WER9725-277-300  
15. Olivera, I., Pérez, C.G., Lazarov, L. et al. Cost minimization analysis of a hexavalent vaccine in Argentina. BMC Health Serv Res 23, 1067 (2023). https://doi.org/10.1186/s12913-023-10038-0
16. Seinfeld J, Rosales ML, Sobrevilla A, López Yescas JG. Economic assessment of incorporating the hexavalent vaccine as part of the National Immunization Program of Peru. BMC Health Serv Res. 2022 May 16;22(1):651. doi: 10.1186/s12913-022-08006-1. PMID: 35570278; PMCID: PMC9109284.
17. Idoko OT, Hampton LM, Mboizi RB, et al. Acceptance of multiple injectable vaccines in a single immunization visit in The Gambia pre and post introduction of inactivated polio vaccine. Vaccine. 2016;34(41):5034-5039. doi: https://doi.org/10.1016/j.vaccine.2016.07.021
18. Hanani Tabana, Dudley L, Knight S, et al. The acceptability of three vaccine injections given to infants during a single clinic visit in South Africa. BMC Public Health. 2016;16(1). doi: https://doi.org/10.1186/s12889-016-3324-2
19. Pelissier JM, Coplan PM, Jackson LA, May JE. The effect of additional shots on the vaccine administration process: results of a time-motion study in 2 settings. Am J Manag Care. 2000 Sep;6(9):1038-44.
20. Al-Bashir L, Ismail A, Aljunid SM. Parents‘ and healthcare professionals’ perception toward the introduction of a new fully liquid hexavalent vaccine in the Malaysian national immunization program: a cross-sectional study instrument development and its application. Front Immunol. 2023;14:1052450.
21. De Coster I, Fournie X, Faure C, Ziani E, Nicolas L, Soubeyrand B, Van Damme P. Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines. A time and motion study. Vaccine. 2015;33(32):3976–82.
22. Esteve IC, Fernández PF, Palacios SL, Rodrı́guez MJ, Vino HP, Ortega BR, Nieto Nevot ML, Manch´on GD, L´opez-Belmonte J-L. Health care professionals’ preference for a fully liquid, ready-to-use hexavalent vaccine in Spain. Prev Med Rep. 2021;22:101376.
23. World Health Organization. Immunization data: African region. Available at: https://immunizationdata.who.int/dashboard/regions/african-region
24. Findlater A, Bogoch II. Human Mobility and the Global Spread of Infectious Diseases: A Focus on Air Travel. Trends Parasitol. 2018 Sep;34(9):772-783. doi: 10.1016/j.pt.2018.07.004. Epub 2018 Jul 23. PMID: 30049602; PMCID: PMC7106444.
25. World Health Organization. Immunization data: Mauritius. Available at: https://immunizationdata.who.int/dashboard/regions/african-region/MUS
26. World Health Organization (2025) Fully funded Gavi, the Vaccine Alliance, is a lifeline for child survival, says WHO. Available at: https://www.who.int/news/item/28-03-2025-fully-funded-gavi–the-vaccine-alliance–is-a-lifeline-for-child-survival–says-who

The post An Expert Perspective from Algeria on Hexavalent Vaccine Adoption appeared first on Medika Life.

Behind every budget shift lies a ripple effect, and today, global healthcare is at the receiving end. The result is shrinking access, rising costs, and widening inequities. The impact of geopolitical decisions is rarely confined to borders, it now extends into clinics, hospitals, and communities. What we are witnessing is not just a funding gap, but a structural shift in how the world values health.

The silent reallocation

Over the past years, global defense spending has surged to record levels. According to the Stockholm International Peace Research Institute (SIPRI), global military expenditure rose by 9.4% in real terms to $2718 billion in 2024, the highest global total ever recorded by SIPRI and the 10th year of consecutive increases. The total military expenditure accounted for 2.5% of the global gross domestic product (GDP) in 2024. These figures are expected to climb further following the June 2025 commitment by North Atlantic Treaty Organization (NATO) members to increase defence and security spending to 5% of GDP by 2035, more than twice the earlier 2% benchmark.

Meanwhile, public health budgets are being trimmed or stagnating. The World Health Organization (WHO) has raised serious concerns about the strain on global health systems, pointing to shrinking international aid and ongoing funding shortfalls. In February, Director-General Tedros Adhanom Ghebreyesus highlighted that abrupt and significant reductions in bilateral assistance have severely disrupted healthcare services across multiple countries, describing 2025 as “one of the most challenging years” in the organization’s history.

As per the WHO, an estimated 4.6 billion people worldwide still do not have access to essential health services, while around 2.1 billion experience financial strain due to healthcare expenses. Compounding this challenge, the global health workforce is projected to face a shortfall of 11 million professionals by 2030, with nurses accounting for more than half of this gap. When 4.6 billion people lack access to essential services, this is not only a development failure, but also a global stability risk – translating into fewer vaccinations, delayed disease surveillance, and weakened emergency response systems.

The global policy conversation increasingly treats defence spending as essential security investment. Health spending, however, is still framed as social expenditure rather than strategic infrastructure. This shift is particularly devastating for LMICs, where international aid often fills critical gaps.

Conflict and the collapse of care

Conflict has long been a stress test for health systems, but the consequences today are deeper and more far-reaching. As the Russia–Ukraine war entered its fifth year in 2026, Ukraine’s health system faced unprecedented strain, with attacks on healthcare rising nearly 20% in 2025 alone. Since the full-scale invasion began, the WHO has documented at least 2,881 attacks targeting hospitals, health workers, ambulances, and medical infrastructure, severely disrupting care delivery. Health outcomes have deteriorated sharply, with 59% of people in frontline areas reporting poor health, alongside surging mental health issues, cardiovascular conditions, and widespread lack of access to essential medicines. Intensified attacks in 2025, including a spike in strikes on medical warehouses, have further crippled supply chains.

In the aftermath of the war in Gaza, the region’s health system remains on the brink of collapse despite months of humanitarian efforts and intermittent pauses in fighting. Widespread damage to hospitals, severe shortages of medicines, and a surge in patients continue to overwhelm already fragile services. Many facilities operate at drastically reduced capacity, with critical treatments, including cancer care, meeting only a fraction of demand, while rising cases of skin and respiratory illnesses place further strain on the system. Healthcare workers, operating under extraordinary pressure and with limited resources, are struggling to manage overwhelming caseloads each day amid ongoing supply constraints and infrastructure damage. The crisis extends well beyond acute injuries, as patients with chronic illnesses face dangerous interruptions in care and deteriorating living conditions, turning access to healthcare into a daily struggle for survival.

Meanwhile, after three years of conflict, the Sudan war has evolved into the world’s largest humanitarian and health crisis, with 34 million people in need of aid and 21 million lacking access to basic healthcare. The system is collapsing under the combined weight of widespread disease outbreaks, acute malnutrition affecting over 4 million people, and relentless attacks on healthcare infrastructure—37% of facilities are now non-functional. As infectious diseases surge and funding falls short, Sudan’s health crisis continues to deepen, turning basic healthcare access into a matter of survival for millions.

What distinguishes the current moment is the scale of global interdependence. Earlier crises were largely contained within regions. Today, disruptions are transmitted across borders through tightly integrated supply chains, financing systems, and health workforces. The Ukraine conflict, for instance, has affected global pharmaceutical logistics and energy prices, indirectly increasing healthcare costs across Europe, Asia, and beyond. The result is not just localized breakdowns, but a systemic fragility in global health security.

Conflict as a cost multiplier in health delivery

Healthcare systems are tightly linked to global supply chains, making them highly vulnerable to geopolitical disruptions. When conflicts interrupt trade routes, restrict exports, or trigger sanctions, costs rise almost immediately, across pharmaceuticals, medical devices, and even basic supplies.

Energy shocks add further pressure. Hospitals, being energy-intensive, face higher operating costs as fuel and electricity prices climb. In conflict zones, even critical functions like vaccine cold chains and intensive care become difficult to sustain. The result is a steady increase in healthcare costs, one that is unevenly felt. While high-income countries may cushion the impact through insurance and subsidies, LMICs face a harsher reality, where rising out-of-pocket expenses can push millions into poverty.

At the same time, conflicts are driving up demand for care. Displacement, malnutrition, and infectious disease outbreaks are becoming more frequent, often compounded by climate-related crises. This creates a vicious cycle. Underfunded systems struggle to respond, outcomes worsen, and long-term costs escalate as preventable issues turn into full-blown crises.

Health communicators bridging gaps in a fragmented world

In times of systemic stress, communication becomes a strategic imperative. Health communicators are no longer just interpreters of science. They are interpreters of risk, resilience, and national preparedness. Their role is to translate complex realities into actionable understanding, to advocate for evidence-based decision-making, and to maintain trust in institutions. In today’s environment, narrative gaps are becoming policy gaps. When health is absent from security conversations, it is often absent from security budgets.

In the current context, communicators must:

• Elevate the narrative around health as a security priority, not a secondary concern.
• Highlight the human impact of budget cuts, moving beyond statistics to real stories.
• Counter misinformation proactively, especially in conflict-affected and resource-constrained settings.
• Support policy advocacy, ensuring that health remains central in national and global agendas.

Equally important is the need for communicators to adopt a more systems-oriented approach. This means connecting the dots between geopolitical decisions and health outcomes, helping stakeholders understand that these are deeply interconnected challenges. Investing in health is not just a moral imperative; it is an economic and strategic one. Strong health systems contribute to productivity, stability, and resilience. They are foundational to national security in the broadest sense.

Governments, multilateral organizations, private sector players, and civil society must come together to reassert the importance of health in the global agenda. Innovative financing mechanisms, public-private partnerships, and more efficient use of resources can help bridge funding gaps. But without political will, these solutions will remain insufficient.

If current trajectories persist, the consequences will extend far beyond strained health systems, they will reshape how societies absorb risk, respond to crises, and sustain economic stability. Healthcare cannot remain the residual line item in a world that is becoming more volatile, more interconnected, and more vulnerable. Narratives shape priorities, and priorities shape funding. If health continues to be framed as a cost rather than a cornerstone of resilience, it will keep losing ground to more immediate, visible threats. That framing must change urgently and decisively. Over the next decade, the countries that succeed in protecting population health will not necessarily be those spending the most on healthcare, but those most effectively integrating health into national security thinking. The real question before policymakers and global leaders is whether nations can remain economically stable, politically resilient, or socially secure while treating health as a

The post The Hidden Cost of Global Conflict: Why Health Security Is the First Casualty appeared first on Medika Life.